PT-141, with the fine print attached
A tanning-research detour became a medicine for low sexual desire. The name travelled farther than the approval.
PT-141 origins and US approval
A peptide explored for tanning produced sexual responses. From that unexpected turn came PT-141, now called bremelanotide. The history of melanocortin therapeutics traces its relationship to melanotan-II; an early development profile still describes a nasal spray intended for male and female sexual dysfunction. The polished version sounds wrong to my ear: PT-141 did not begin with one tidy purpose. The biology never became quite so tidy either.
The eventual US approval in June 2019 covered acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women. HSDD means low sexual desire that causes marked distress, rather than simply wanting sex less often. The prescribing information does not approve bremelanotide for men, postmenopausal women or sexual performance. Those distinctions are the fine print that tends to fall away when the research code becomes a reputation.
PT-141 and bremelanotide
PT-141 and bremelanotide name the same molecule: a synthetic peptide, a short chain of amino acids, arranged in a ring. Its main targets are melanocortin receptors in the brain, chiefly MC4R and MC3R. The foundational pharmacology report includes rat and nonhuman-primate experiments, along with early erectile-activity findings in men with erectile dysfunction. Those are different kinds of evidence inside the same paper, not a male approval.
I was initially more interested in the erections than in the desire question. The female-rat study of sexual solicitation turned that emphasis around: PT-141 increased desire-driven approaches without changing reflexive sexual behaviour or general movement. In rats, that is a surprisingly particular result. It is also why the mechanism page spends time on the difference between wanting, arousal and reward.
RECONNECT results
The RECONNECT trials in 1,267 premenopausal women with HSDD found improved desire and reduced distress compared with placebo over 24 weeks. I respect the fact that the trials met their endpoints; I doubt the jump from that result to a general promise of restored sexual life. The benefits page sets out the exact changes, and the side-effect account gives nausea the space it deserves.
For an amount, a unit or a timing question, PT-141 dosage calls for the label rather than an anecdote. The approved medicine and material described as a research chemical share a name, but the latter sits outside the pharmaceutical approval system.
European status and delivery questions
The first-approval review documents a United States approval. It cannot settle current European status. I cannot establish the latest PT-141 EMA news from this US record, and permission or availability elsewhere requires evidence beyond a US label.
Delivery, or 配達, introduces another question entirely. A result for pt141配達 does not establish what would arrive, its identity, its concentration or its regulatory standing. The forensic analysis of illicit melanocortin samples is a useful antidote to treating a familiar name as proof of contents. The about page explains what RxPT141 actually is.